- Treffer 1 von 1
CARS imaging advances early diagnosis of cardiac manifestation of Fabry disease
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-284427
- Vibrational spectroscopy can detect characteristic biomolecular signatures and thus has the potential to support diagnostics. Fabry disease (FD) is a lipid disorder disease that leads to accumulations of globotriaosylceramide in different organs, including the heart, which is particularly critical for the patient’s prognosis. Effective treatment options are available if initiated at early disease stages, but many patients are late- or under-diagnosed. Since Coherent anti-Stokes Raman (CARS) imaging has a high sensitivity for lipid/proteinVibrational spectroscopy can detect characteristic biomolecular signatures and thus has the potential to support diagnostics. Fabry disease (FD) is a lipid disorder disease that leads to accumulations of globotriaosylceramide in different organs, including the heart, which is particularly critical for the patient’s prognosis. Effective treatment options are available if initiated at early disease stages, but many patients are late- or under-diagnosed. Since Coherent anti-Stokes Raman (CARS) imaging has a high sensitivity for lipid/protein shifts, we applied CARS as a diagnostic tool to assess cardiac FD manifestation in an FD mouse model. CARS measurements combined with multivariate data analysis, including image preprocessing followed by image clustering and data-driven modeling, allowed for differentiation between FD and control groups. Indeed, CARS identified shifts of lipid/protein content between the two groups in cardiac tissue visually and by subsequent automated bioinformatic discrimination with a mean sensitivity of 90–96%. Of note, this genotype differentiation was successful at a very early time point during disease development when only kidneys are visibly affected by globotriaosylceramide depositions. Altogether, the sensitivity of CARS combined with multivariate analysis allows reliable diagnostic support of early FD organ manifestation and may thus improve diagnosis, prognosis, and possibly therapeutic monitoring of FD.…
Autor(en): | Elen Tolstik, Nairveen Ali, Shuxia Guo, Paul Ebersbach, Dorothe Möllmann, Paula Arias-Loza, Johann Dierks, Irina Schuler, Erik Freier, Jörg Debus, Hideo A. Baba, Peter Nordbeck, Thomas Bocklitz, Kristina Lorenz |
---|---|
URN: | urn:nbn:de:bvb:20-opus-284427 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Medizinische Fakultät / Institut für Pharmakologie und Toxikologie | |
Medizinische Fakultät / Medizinische Klinik und Poliklinik I | |
Medizinische Fakultät / Deutsches Zentrum für Herzinsuffizienz (DZHI) | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | International Journal of Molecular Sciences |
ISSN: | 1422-0067 |
Erscheinungsjahr: | 2022 |
Band / Jahrgang: | 23 |
Heft / Ausgabe: | 10 |
Aufsatznummer: | 5345 |
Originalveröffentlichung / Quelle: | International Journal of Molecular Sciences (2022) 23:10, 5345. doi:10.3390/ijms23105345 |
DOI: | https://doi.org/10.3390/ijms23105345 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | Fabry Disease (FD); Gb3 and lyso-Gb3 biomarkers; Raman micro-spectroscopy; cardiovascular diseases; coherent anti-Stokes Raman scattering (CARS) microscopy; immunohistochemistry; multivariate data analysis |
Datum der Freischaltung: | 19.04.2023 |
Datum der Erstveröffentlichung: | 11.05.2022 |
EU-Projektnummer / Contract (GA) number: | 101016923 |
OpenAIRE: | OpenAIRE |
Open-Access-Publikationsfonds / Förderzeitraum 2022 | |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |